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Abstract – The aim of this study was to evaluate the in situ detection of living mycobacterium TB rRNA by the mycobacte-
rium TB direct assay (MTD) and its clinical significance in the early diagnosis of extrapulmonary TB. Eighty-six patients 
were recruited from the Shanghai Public Health Clinical Center from June to November in 2010, having been diagnosed 
with extrapulmonary TB, including tuberculous peritonitis (n=22), lymphatic TB (n=21), tuberculous meningitis (n=15), 
HIV-associated TB (n=13), nephroTB (n=9), spinal TB (n=2), cutaneous TB (n=13), parotid TB (n=1), chest wall TB 
(n=1), intestinal TB (n=1). One hundred and five extrapulmonary specimens, including CSF, puncture fluid, drainage, 
pleural fluid, urine, secretion, ascites, lymphatic tissue and marrow were collected from the patients. The samples were 
examined using acid-fast stain, solid culture, liquid culture and MTD in parallel. In MTD, the target segments of MTB 
rRNA in either cultures or clinical specimens were amplified prior to being qualitatively detected with the hybridization 
protection assay (HPA). The sensitivities of MTD and acid-fast staining in liquid and solid cultures were 48.6%, 41.9%, 
20.0% and 14.3%, respectively. MTD sensitivity was higher than that of the others and its specificity was 100%. We con-
cluded that MTD rRNA detection is an effective, rapid, convenient, sensitive and reliable method for the early diagnosis 
of extrapulmonary TB.
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INTRODUCTION
 Mycobacterium TB (MTB) is the causative agent 
of tuberculosis (TB). Successful disease control 
relies on early identification of suspicious sub-
jects and rapid detection of MTB. Traditional 
diagnostic  methods  include  smear  staining  of 
acid-fast bacilli (AFB) in liquid or solid culture. 
Culture results are usually not available before 
2 to 3 weeks, whereas AFB staining lacks sensi-
tivity and specificity. Infections with MTB often 
cause pulmonary disease but can also involve 
extrapulmonary organs such as the skin, bone, 
kidney, lymph node and marrow (Ashford et al., 
2001; Chao et al., 2002). Extrapulmonary TB ac-
counts for 25-30% of total TB and its mortality 
accounts  for  14.1-17.6%  of  overall  TB-caused 
death  (Huang  et  al.,  2000).  Diagnosis  of  ex-
trapulmonary TB is even more difficult due to 
its complicated clinical manifestation and lack 
of  specific  features.  Recently,  many  methods 
have been developed to meet such needs, and 
nucleic acid amplification is one of them. Due to 
their natural ability to recognize one single or-
ganism, nucleic acid amplification methods have 
the potential to decrease dramatically diagnostic 
duration  as  well  as  increase  detection  specifi-
city. IS6110 or 16S rRNA genes have been used 1004 HUI-ZHANG ZHANG ET AL.
as targets in nucleic acid amplification (Watter-
son et al., 2000). Several kits that use 16S rRNA 
sequences  as  probes  or  amplification  primers 
are  commercially  available  for  the  identifica-
tion of mycobacteria (Drobniewski et al., 2000; 
St Amand et al., 2005; Tottey, 2013; Lazzeri et 
al.,2012). We selected the quickest methodology 
for the detection of mycobacteria in both culture 
and extrapulmonary tissue in situ (St Amand et 
al., 2005) and compared it with other conven-
tional methods, hoping to improve the early di-
agnosis and treatment of extrapulmonary TB.
MATERIALS AND METHODS
Specimen origins
Eighty-six patients diagnosed with extrapulmonary 
TB, including tuberculous peritonitis (n=22), lym-
phatic  TB  (n=21),  tuberculous  meningitis  (n=15), 
HIV-associated  TB  (n=13),  nephrotuberculosis 
(n=9), spinal TB (n=2), cutaneous TB (n=13), pa-
rotid TB (n=1), chest wall TB (n=1) and intestinal 
TB (n=1), were recruited from the Shanghai Pub-
lic Health Clinical Center from June to November 
in 2010. 105 extrapulmonary specimens including 
CSF (n=29), puncture fluid (n=24), drainage (n=15), 
pleural fluid (n=14), urine (n=9), secretion (n=9), 
ascites  (n=3),  lymphatic  tissue  (n=1)  and  marrow 
(n=1) were collected from the patients. Thirty-one 
subjects with non-TB such as cryptococcal meningi-
tis or liver disease were recruited as negative control. 
These patients were characterized by definite diag-
nosis, no history of TB, and on-going TB was ruled 
out by chest X-ray (CXR) or lab tests. The examined 
specimens included CSF (n=13), ascites (n=7), pleu-
ral fluid (n=4), puncture fluid (n=3), secrete (n=2), 
drainage (n=1) and urine (n=1).
Instruments and reagents
The MTD kit was purchased from Gen-Probe UK 
Co Ltd, and the MTB antigen detection reagent kit 
(colloidal gold) was from Hangzhou Genesis Bio-
detection & BiocontrolLtd; Acid fast stain (Zhuhai, 
Beisuo).
MTD detection
Mycobacteria were released from host cells by ultra-
sonication and heated to denature nucleic acid and 
untwisted rRNA. The target segment of rRNA was 
exponentially amplified at 42°C. The complementary 
sequence  of  amplification  products  was  bound  by 
chemiluminescent-labeled probes and subsequently 
detected with HPA. Once the RNA:DNA complex 
was stabilized, successfully hybridized probes were 
selected and visualized in a chemiluminescent de-
tector. Detection was according to the assay instruc-
tions; all batches passed quality control.
Other methods
Each sample was solid or liquid cultured acid-fast 
stained according to the Ziehl-Neelsen method. The 
solid culture followed the L-J medium culture proto-
col; the liquid culture followed the requirements of 
BACTEC MGIT 960.
RESULTS
Results  of  MTB  detection  in  105  extrapulmonary 
samples with MTD, culture and smear in parallel, are 
shown in Table 1. The sensitivity of the four methods 
was MTD 48.6% (51/105), smear 41.9% (44/105), liq-
uid culture 20.0% (21/105), and solid culture 14.3% 
(15/105). The sensitivity of MTD was significantly 
different from that of the liquid and solid culture 
(P<0.01), but the same as that of the smear (p>0.05). 
All liquid culture positive specimens were also MTD 
positive and the specificity of MTD was 100%. All 
MTD, culture and smear results in the control group 
were negative. The results of MTB detection in 105 
specimens with MTD, culture and smear are shown 
in Tables 2-5.
DISCUSSION
Gen-Probe MTD is a molecular diagnostic reagent 
approved by the FDA and SFDA to identify MTB 
(Coelho  et  al.,  2008).  It  is  a  chemiluminescent-
labeled probe capable of detecting MTB rRNA by 
binding a complementary nucleic acid in cultured or MYCOBACTERIUM TB DIRECT ASSAY 1005
non-cultured specimens for diagnostic purpose and 
is characterized by both high sensitivity and high 
specificity, which enables it to rapidly differentiate 
MTB  from  mycobacterium  avium,  mycobacterium 
intracellulare, mycobacterium kansasii and mycobac-
terium gordonae. While its clinical diagnostic signifi-
cance has been verified (Bergmann et al., 1999), its 
extrapulmonary application has yet to be elucidated. 
The present study was focused on the in situ detec-
tion of MTB rRNA in clinical specimens. 
Extrapulmonary TB accounts for 25-30% of all 
TB. The percentage is 9.7-11.8% in China, and its 
mortality accounts for 14.1-17.6% of all TB-caused 
death (Huang et al., 2000). Diagnosis of extrapul-
monary TB is difficult due to its complicated clinical 
manifestation and lack of specific features. At present, 
clinical examination combined with culture, micro-
scopic examination of direct smear staining and ad-
juvant chest X-ray is still golden standard diagnostic. 
All these methods are based on clinical symptoms, 
Table 1. The results of MTB detection in 105 extrapulmonary samples with MTD, culture and smear in parallel
            Methods
Diagnosis  
MTD Positive Smear Positive Solid Culture Positive Liquid Culture Positive Number
Tuberculous Peritonitis 13 10 1 3 29
LymphoTB 20 18 11 11 28
Tuberculous Meningitis 7 3 1 3 18
AIDS * 4 6 0 2 15
NephroTB 1 2 1 2 contaminated 9
Spinal TB 2 2 0 1 2
Cutaneous TB 1 1 0 0 1
Parotid TB 1 1 1 1 1
Chest Wall TB 1 1 0 0 1
Intestinal TB 1 0 0 0 1
Total 51 44 15 21 105
*In all 15 AIDS cases, 10 were combined with tuberculous meningitis and 5 with tuberculous peritonitis
Table 2. The results of MTB detection in 105 specimens with MTD, culture and smear
  Methods
Diagnosis
MTD Positive Smear Positive Solid Culture Positive Liquid Culture Positive Number
CSF 12 6 2 6 29
Puncture Fluid 13 12 5 5 23
Drainage 13 12 5 7 15
Pleural Fluid 4 3 0 0 14
Urine 1 2 1 2 contaminated 9
Secrete 3 7 0 1 9
Ascites 3 0 0 0 3
Lymphatic Tissue 2 1 2 2 2
Marrow 0 1 0 0 1
Total 51 44 15 21 105
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Table 3. The results of 44 smear-positive detected with MTD, culture and smear in parallel
  Methods
Diagnosis
MTD Positive Smear Positive Solid Culture Positive Liquid Culture Positive
CSF 4 1 2 6
Puncture Fluid 10 5 5 12
Drainage 12 5 7 12
Pleural Fluid 2 0 0 3
Urine 1 1 1 contaminated 2
Lymphatic Tissue 1 1 1 1
Secrete 3 0 1 7
Marrow 0 0 0 1
Total 33 13 16 44
Table 4. The results of 61 smear-negative detected with MTD, culture and smear in parallel
  Methods
Diagnosis
MTD Positive Smear Positive Solid Culture Positive Liquid Culture Positive
CSF 8 1 4 23
Puncture Fluid 3 0 0 11
Drainage 1 0 0 3
Pleural Fluid 2 0 0 11
Urine 0 0 1 contaminated 7
Ascites 3 0 0 3
Lymphatic Tissue 1 1 1 1
Secrete 0 0 0 2
Total 18 2 5 61
Table 5. The results of 51 MTD-positive detected with MTD, culture and smear in parallel
  Methods
Diagnosis
MTD Positive Smear Positive Solid Culture Positive Liquid Culture Positive
CSF 4 2 6 12
Puncture Fluid 10 3 5 13
Drainage 12 5 7 13
Pleural Fluid 2 0 0 4
Ascites 0 0 0 3
Urine 1 1 1 contaminated 1
Lymphatic Tissue 1 2 2 2
Secrete 3 0 1 3
Total 33 13 21 51MYCOBACTERIUM TB DIRECT ASSAY 1007
which limit their ability to detect sub-clinical infec-
tion. The direct smear is convenient, rapid and inex-
pensive, and it is still the diagnostic of choice, but its 
clinical application is limited by factors such as: 1) 
a low positive rate, approximately 10% (0-87%), less 
than 104/ml is not detectable; 2) poor specificity, as all 
species of mycobacterium can be positively stained, 
and another test is necessary to confirm this; 3) in-
ability to discern living from dead cells; 4) limited 
(Hooja et al., 2011). In this study, 11 smear-positive 
cases were MTD negative, and possible causes in-
cluded 1) false positive smear test of non-tuberculous 
mycobacteria; 2) 7 out of those 11 were follow-up 
patients who had received treatment, and these false 
positives could have resulted from killed bacteria; 3) 
mishandling of specimens, existence of amplification 
inhibitor  or  incomplete  digestion.  There  was  one 
case where the smear was positive but the first MTD 
was negative; MTD turned positive the second time 
after another around of digestion. Limited quantities 
of specimens or templates could interfere with the 
sensitivity. We also found there 18 smear-negative 
cases were MTD-positive, indicating that the smear 
test was influenced by multiple factors.
In a study of CSF collected from 132 tuberculous 
meningitis patients, Thwaites et al. (2004) showed 
that a relatively large volume of CSF (>6 ml) was an 
independent factor determining its ability to detect 
acid-fast bacilli, and that an average of 30 min mi-
croscopic examination as well as appropriate repeats 
could improve the detection rate. Additionally, the 
length of disease course, neutrophil ratio, lactic acid 
level and CSF/serum glucose ratio were all report-
ed to be associated with acid-fast bacilli detection. 
The culture possesses a mildly increased detection 
rate and might be able to guide clinical treatment by 
providing drug sensitivity data, however, it requires 
at least 103~104 bacilli/ml to be positively detected, 
which makes it more difficult to culture, especially 
bacilli with defective cell walls or compromised by 
chemotherapy. Considering the lengthy growth pe-
riod (approx 3-8 weeks), which could be reduced to 
3-10 days by an advanced Bactec culture system to-
gether with gene probe technology, its low positive 
rate (as low as 20-30%), and its inability to differenti-
ate MTB and nontuberculous mycobacteria, culture 
is obviously not a favorable tool for the diagnosis of 
MTB infection. To improve the clinical efficacy of 
anti-TB medicines, the development of a rapid spe-
cies identification assay is warranted (Tomioka et al., 
2006). Contamination is another issue, especially of 
urine samples. Due to the existence of normal flora, 
the contamination rate of liquid culture is still high 
in spite of decontamination procedures. In this study, 
2 of a total of 9 samples were contaminated, of which 
1 was detected positive with MTD, indicating MTD 
was preferred to avoid potential contamination of 
urine samples and increase detection sensitivity si-
multaneously. The positive rates of the smear test and 
culture in the detection of extrapulmonary TB are 
low because of the limited quantity of bacteria.
In this study, all 21 liquid culture positive speci-
mens were MTD positive as well. The MTD assay 
can detect MTB rRNA in cultured or non-cultured 
specimens.  Thirty-one  extrapulmonary  specimens 
were examined with MTD, culture and smear in par-
allel, and all results turned out to be negative, imply-
ing 100% specificity of MTD in the detection of ex-
trapulmonary TB. The samples were TMA amplified 
prior to HPA for qualitative analysis of MTB rRNA, 
and the whole process only took 2.5-3.5 hours. Since 
rRNA is believed to be detectable only in live bac-
teria  due  to  its  quick  degradation  after  the  death 
of bacteria, the contribution of dead bacteria will 
be ruled out in a positive outcome (Kahlisch et al., 
2012). Because of its fragile single strand structure 
and vulnerability to degrade, a false positive or cross 
contamination are much less likely. The application 
of MTD in the detection of MTB in sputum samples 
has been repeatedly verified. In this study, we selected 
11 specimens to be tested with MTD, TB DNA, cul-
ture and smear in parallel, finding 6 smear positives, 
including 2 cases positive for all four tests and 1 posi-
tive for all except MTD, which was later proved to be 
nontuberculous mycobacteria. 48.6% sensitivity and 
100% specificity were identified in this study with a 
positive rate higher than that of culture. MTD is a 
rapid, sensitive and specific test of extrapulmonary 
TB. The quality of clinical specimens is essential for 
the accuracy of the test, and a correct way for speci-1008 HUI-ZHANG ZHANG ET AL.
men collection and a sufficient sample may improve 
detection rate (Havlir et al., 1999). For those patients 
with combined HIV infection, the lack of extrapul-
monary symptoms at the end stage due to compro-
mised lymphocyte-mediated immune response may 
interfere with the diagnosis and prognosis of the dis-
ease (Maher et al., 2005). Among all 15 AIDS sam-
ples, MTD was positive in 4 cases including 3 smear 
positive and 1 smear negative; 6 cases were positive 
for smear including 3 MTD negative cases, and the 
sensitivity of MTD in detection of HIV infection-
related extrapulmonary TB was 33.3% (Watterson et 
al., 2000; Thwaites et al., 2004). 
A rapid, accurate diagnostic is essential for TB 
prevention. We demonstrated that MTD carried the 
most important clinical significance in the diagnosis 
of extrapulmonary TB with its ability to detect MTB 
rRNA in situ. With the development of molecular 
biotechnology, it has become possible to establish 
a diagnosis of TB within one day, which could help 
with early diagnosis and the initiation of treatment at 
the early stage of the disease.
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